cancer of unknown primary

The company's Q2 revenue growth was driven by a 74 percent increase in revenues from the analytical services it provided to the VA MVP program.

Twist will give Takeda access to its phage display libraries to help Takeda discover and validate antibodies needed for the development of new biologics. 

Abcam will develop custom protein-based reagents for targets identified by researchers funded by Cancer Research UK. 

The company said Q1 revenue growth was driven by an increase in testing volume and analytical services provided to the US Department of Veterans Affairs.

An error in the chromosome bridge formation process can trigger mutational events leading to gene amplification and genome instability.

The company said Q4 revenue growth was driven by an increase in testing volume and analytical services provided to the US Department of Veterans Affairs.

Researchers re-examined whole-genome and whole-transcriptome sequencing TCGA studies from 33 cancer types and found unique microbial signatures.